A critical question currently under investigation is whether using a dual SGLT1/2 inhibitor, such as Sotagliflozin (SOTAG), may offer greater therapeutic benefits compared to single SGLT2 inhibitors, such as Empagliflozin (EMPA), in the treatment of cardiorenal disease in both patients with and without diabetes. Here, SLC5A1 is linked to diabetes mellitus.